Skip to content

AVLN: Held by 5 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc.

AVLN

Held by 5 specialist biotech funds

High ConvergenceHigh short interest · No specialist buying

5 funds opened new positions. Next phase2 readout (AP02): Dec 2026. Short interest: 4.7% of float.

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Share

Medical - PharmaceuticalsCEO: Lyn BaranowskiIPO: 2026Website ↗

Avalyn Pharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). The company was founded by Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar on May 27, 2011 and is headquartered in Boston, MA.

Score Holdings Short Interest Catalysts Insiders Research

Signal Score

6.5/10

5 funds opened new positions●●

No recent insider activity●●

Phase2 readout expected Dec 2026●●

Held by 5 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

5 specialist funds hold AVLN with a Phase 2 in 125 days for AP02 (Idiopathic Pulmonary Fibrosis (IPF))

+2 more upcoming catalysts

Deerfield Management Eventide Asset Management Perceptive Advisors Baker Bros. Advisors Rock Springs Capital

Fund Holdings

5 fund convergence

Deerfield ManagementNew

Eventide Asset ManagementNew

Perceptive AdvisorsNew

Baker Bros. AdvisorsNew

Rock Springs CapitalNew

AI Signal

Avalyn Pharma (AVLN) — New Position Signal

Eventide initiated a $45.3M new position in AVLN, a meaningful opening stake in a pulmonary fibrosis-focused name with the nearest hard catalyst being the AP02 Phase 2 IPF readout expected by end of 2026, followed by AP01 data across PPF/SSc-PF by mid-2027. Five specialist biotech funds now hold this name — Deerfield, Baker Bros., Perceptive, and Rock Springs alongside Eventide — representing meaningful smart-money convergence in a rare, high-unmet-need fibrosis franchise.

Unlock full AI analysis — 14-day free trial

Short Interest

High short interest

Short Shares

2.07M

Change

-5.4%

Days to Cover

10.0

% of Float

4.7%

Settlement

Aug 14, 2026

Short interest over 7 periods

Catalysts

Phase 2Q4 2026AP02Idiopathic Pulmonary Fibrosis (IPF)NCT07194382

Phase 2Q2 2027AP01Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic SclerosisNCT06329401

Phase 2Q4 2031Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)NCT06951217

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13GPerceptive Advisors6.0%May 7, 2026

Position Details

Deerfield ManagementNEW POSITIONAug 14, 2026

Start free trialfor share counts, dollar values & AI analysis

4 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Also Held by These Funds

IDYA1 fund IMTX1 fund IMNM1 fund IMVT1 fund INCY1 fund CRNX1 fund CYTK1 fund MIRM1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: